RCS - Adv Medical Solutns. - Upcoming Investor Conferences

Advanced Medical SolutionsAnnouncement

Mon 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nRSa8152Ea&default-theme=true

RNS Number : 8152E  Advanced Medical Solutions Grp PLC  27 October 2025

27 October 2025

 

Advanced Medical Solutions Group plc

("AMS" or the "Group")

 

AMS to participate in upcoming investor conferences in November and December

 

 

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), the innovative
tissue healing medical device company delivering high-performing,
cost-effective solutions for better patient outcomes, today announces that the
Group will be participating in the following investor conferences in November
and December:

·      Investec UK CEO Conference, London

Date: 11 November 2025

Format: One-on-one and group investor meetings

 

·      Berenberg European Conference, Windsor

Date: 4 December 2025

Format: One-on-one and group investor meetings

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc       Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 Optimum Strategic Communications           Tel: +44 (0) 20 4566 8543
 Mary Clark / Nick Bastin / Isabelle Abdou  AMS@optimumcomms.com

 Investec Bank PLC (NOMAD & Broker)         Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 Berenberg (Joint Broker)                   Tel: +44 (0)20 3207 7800
 Toby Flaux / Detlir Elezi

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is an innovative tissue healing medical device company delivering
high-performing, cost-effective solutions that match or surpass market
leaders, clinically, technically, and commercially. From adhesives and
sealants, to biosurgical devices and sutures, AMS's products offer superior
usability, quality and design. AMS's strength lies in combining advanced
material science with applicator device design and development, in
collaboration with surgeons and Key Opinion Leaders, creating differentiated
devices that improve patient outcomes without compromising quality or
affordability.

AMS's scalable, resilient business model is built on disciplined execution,
portfolio focus, and capital efficiency. Its diversified product and
geographic mix mitigates volatility, ensuring consistent performance even when
individual segments fluctuate. Following its acquisition of Peters Surgical,
AMS is unlocking operational and commercial synergies, accelerating its U.S.
and international expansion, and increasing the percentage of sales made
through its direct sales teams. With surgical products driving the lion's
share of group revenues and a clear growth trajectory, AMS is positioned for
scalable growth, margin improvement, and long-term value creation.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEASELAFKSFFA



            Copyright 2019 Regulatory News Service, all rights reserved